Phaseline

Companies › U: The Mind Company

U: The Mind Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sphere V3.0
Amplitude-modulated transcranial pulsed random noise stimulation (am-tPRNS)
–Phase 1PARKINSON DISEASE (Disorder)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07182058Sphere V3.0Phase 1PARKINSON DISEASE (Disorder)NeurologyMar 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.